top of page
< Back

Gemcitabine

吉西他濱

Mechanism of action:

Gemcitabine 是一種去氧胞苷核苷（deoxycytidine nucleoside）類似物。Gemcitabine 進入細胞後，先由去氧胞苷激酶（deoxycytidine kinase）磷酸化為 gemcitabine monophosphate（dFdCMP），再轉化為 dFdCDP 與 dFdCTP。dFdCDP 可抑制核苷酸還原酶（ribonucleotide reductase），降低去氧核苷酸（dNTP）的生成；dFdCTP 會與 dCTP 競爭，被摻入正在合成的 DNA 中，最後 DNA 複製受阻與損傷累積，啟動細胞週期停滯與凋亡路徑。

​Reference(s):

1. Noble S et al. (1997). Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 


2. Toschi L et al. (2005). Role of gemcitabine in cancer therapy. Future Oncol. 


3. Ciccolini J et al. (2016). Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol.

bottom of page